Long-term safety of tezepelumab in patients with asthma: a systematic review and meta-analysis of randomized controlled trials.
| Autor: | Qin J; Radioimmunoassay Center, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China., Wang G; Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China., Han D; Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] 2025 Jan; Vol. 62 (1), pp. 4-13. Date of Electronic Publication: 2024 Aug 02. |
| DOI: | 10.1080/02770903.2024.2385973 |
| Abstrakt: | Objective: Tezepelumab has demonstrated its effectiveness in patients with asthma, but its safety, especially for long-term use, needs to be further explored. This systematic review and meta-analysis aimed to determine the safety of long-term use of tezepelumab in patients with asthma. Data Sources: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Study Selections: Randomized controlled trials (RCTs) on treatment of asthma with tezepelumab, compared with placebo, were reviewed. Studies were pooled to weighted mean differences (WMDs) and risk ratios (RRs), with 95% confidence intervals (CIs). Results: Seven RCTs (enrolling 2050 participants) met the inclusion criteria. Serious adverse event (RR 0.74, 95% CI 0.57 to 0.95), upper respiratory tract infection (RR 0.73, 95% CI 0.55 to 0.96), and asthma (RR 0.61, 95% CI 0.48 to 0.76) were more frequent in the placebo groups. There was no statistically significant difference in the proportion of patients with at least one adverse event (AE), AEs leading to discontinuation of study treatment, all-cause death, influenza, bronchitis, nasopharyngitis, headache, and hypertension between the two groups. Conclusion: Long-term (12-52 wk) use of tezepelumab in patients with asthma does not increase the incidence of adverse events. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|